Ustekinumab (CNTO 1275)

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Also Known As:

Networked: 2034 relevant articles (416 outcomes, 484 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Feldman, Steven R: 34 articles (04/2024 - 07/2010)
2.	Peyrin-Biroulet, Laurent: 29 articles (02/2024 - 03/2015)
3.	Sandborn, William J: 28 articles (02/2024 - 10/2008)
4.	Danese, Silvio: 25 articles (02/2024 - 10/2017)
5.	Puig, L: 24 articles (10/2021 - 09/2010)
6.	Gottlieb, Alice B: 24 articles (01/2021 - 06/2010)
7.	Gisbert, Javier P: 20 articles (02/2024 - 01/2016)
8.	Sands, Bruce E: 19 articles (02/2024 - 10/2012)
9.	Afif, Waqqas: 19 articles (12/2023 - 05/2017)
10.	Warren, Richard B: 19 articles (12/2023 - 03/2010)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 07/08/2019 - "We describe a family carrying a novel heterozygous mutation in CARD14 gene, with childhood-onset erythrodermic psoriasis requiring an unusual extremely high dose (up to 2 mg/kg every 8 weeks) of ustekinumab to achieve disease remission. " 09/30/2015 - "To the best of our knowledge, these are the first cases reported in the literature describing the long-term good efficacy of ustekinumab not only on paradoxical forms of psoriasis induced by anti-TNF-α drugs, but also on the articular involvement in a patient affected by RA and in a patient affected by Sjögren syndrome." 02/01/2014 - "Ustekinumab seems to be the most favorable biologic in term of cost per PASI 75 responder for the treatment of psoriasis and it is cost-effective in all scenarios analyzed. " 05/17/2008 - "Although treatment with ustekinumab every 12 weeks is effective for most patients with moderate-to-severe psoriasis, intensification of dosing to once every 8 weeks with ustekinumab 90 mg might be necessary to elicit a full response in patients who only partially respond to the initial regimen." 05/17/2008 - "Ustekinumab seems to be efficacious for the treatment of moderate-to-severe psoriasis; dosing every 12 weeks maintains efficacy for at least a year in most patients."
2.	Crohn Disease (Crohn's Disease) 12/01/2020 - "Ustekinumab treatment in patients with highly refractory Crohn's disease resulted in high long-term treatment persistence and significantly reduced disease activity, assessed with objective markers for intestinal inflammatory activity." 12/01/2023 - "ustekinumab has proven effective in Crohn's disease (CD). " 06/01/2023 - "Ustekinumab has been proven to be effective for treatment of patients with Crohn's disease; however, 30-40% of patients have been reported to lose clinical response within 2 years. " 04/21/2022 - "Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn's disease (CD). " 02/01/2020 - "We describe an elderly-onset Crohn's disease patient showing a marked remission-maintaining effect with no adverse events after administration of ustekinumab. "
3.	Ulcerative Colitis 10/01/2022 - "Ustekinumab has been shown to be effective for the treatment of ulcerative colitis (UC); however, >40% of patients have suboptimal clinical response after induction and maintenance dosing every 8 weeks.1,2 The best management approach for these patients is unclear. " 09/28/2019 - "Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab." 05/01/2023 - "Ustekinumab has been shown to be effective to induce and maintain clinical, endoscopic and histologic remission in moderate-to-severe ulcerative colitis both in phase 3 and real-world studies, with a favorable safety profile. " 11/01/2023 - "The findings revealed a notable trend: ustekinumab displayed a propensity for yielding higher rates of clinical remission in patients with ulcerative colitis (UC). " 01/01/2019 - "Ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. "
4.	Psoriatic Arthritis 01/01/2023 - "In PsABio (NCT02627768), a prospective, observational study, patients with PsA that were prescribed first- to third-line ustekinumab or a TNFi, and remained on that drug for 3 years, were analysed for change in baseline in PROs (EuroQol-5 dimensions health state VAS [EQ-5D VAS], 12-item Psoriatic Arthritis Impact of Disease questionnaire [PsAID-12; range 0-10], Work Productivity and Activity Impairment for Psoriatic Arthritis questionnaire [WPAI; results expressed as a percentage for each domain]), and the association between PROs and WPAI with effectiveness endpoints, clinical disease activity index for psoriatic arthritis (cDAPSA), low disease activity (LDA)/remission, minimal disease activity (MDA) and very low disease activity (VLDA). " 08/31/2013 - "Ustekinumab significantly improved active psoriatic arthritis compared with placebo, and might offer an alternative therapeutic mechanism of action to approved biological treatments. " 03/08/2018 - "Is ustekinumab effective for psoriatic arthritis with insufficient response to initial treatment?" 06/01/2016 - "Ustekinumab is an effective and safe alternative for patients with anti-TNFα failure in psoriatic arthritis." 11/01/2014 - "Network Meta-Analysis With Baseline Risk Adjustment To Assess The Relative Efficacy Of Ustekinumab In Adult Patients With Active Psoriatic Arthritis."
5.	Necrosis 01/01/2022 - "Ustekinumab is more effective in biologic-naive patients with Crohn’s disease than those who were not responsive to anti–tumor necrosis factor treatment." 01/01/2023 - "We aimed to assess the comparative effectiveness and safety of ustekinumab vs tumour necrosis factor-alpha (anti-TNF) agents after first-line treatment with anti-TNF in CD. " 11/01/2021 - "To evaluate 6-month effectiveness of ustekinumab versus tumour necrosis factor inhibitor (TNFi), analysing predictors of low disease activity (LDA)/remission. " 10/01/2020 - "To evaluate the real-life efficacy of tumour necrosis factor blockers and ustekinumab in PPP and in ACH. " 01/01/2021 - "Twenty-seven active PsA patients were enrolled in an observational/open-label study and underwent biopsies of synovium and paired lesional/non-lesional skin before starting anti-tumour necrosis factor (TNF) (if biologic-naïve) or ustekinumab (if anti-TNF inadequate responders). "

Related Drugs and Biologics

1.	Interleukin-12 (IL 12)
2.	Adalimumab (Humira)
3.	vedolizumab
4.	Infliximab (Remicade)
5.	Monoclonal Antibodies
6.	Interleukin-23 (Interleukin 23)
7.	Etanercept (Enbrel)
8.	secukinumab
9.	Interleukins
10.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

Related Therapies and Procedures

1.	Therapeutics
2.	Biological Therapy
3.	Liver Transplantation
4.	Remission Induction
5.	Subcutaneous Injections